Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Capital Expenditures: 2013-2024

Historic Capital Expenditures for Seres Therapeutics (MCRB) over the last 12 years, with Dec 2024 value amounting to $380,000.

  • Seres Therapeutics' Capital Expenditures fell 93.80% to $8,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $313,000, marking a year-over-year decrease of 73.18%. This contributed to the annual value of $380,000 for FY2024, which is 95.24% down from last year.
  • Latest data reveals that Seres Therapeutics reported Capital Expenditures of $380,000 as of FY2024, which was down 95.24% from $8.0 million recorded in FY2023.
  • Over the past 5 years, Seres Therapeutics' Capital Expenditures peaked at $9.8 million during FY2022, and registered a low of $380,000 during FY2024.
  • Moreover, its 3-year median value for Capital Expenditures was $8.0 million (2023), whereas its average is $6.1 million.
  • In the last 5 years, Seres Therapeutics' Capital Expenditures surged by 1,518.61% in 2021 and then plummeted by 95.24% in 2024.
  • Yearly analysis of 5 years shows Seres Therapeutics' Capital Expenditures stood at $591,000 in 2020, then soared by 1,518.61% to $9.6 million in 2021, then climbed by 2.67% to $9.8 million in 2022, then fell by 18.80% to $8.0 million in 2023, then tumbled by 95.24% to $380,000 in 2024.